Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.

Journal of biochemical and biophysical methods - 30 Jan 2001

Ozdemir V, Basile V S, Masellis M, Kennedy J L

Abstract excerpt

Tardive dyskinesia (TD) is characterized by involuntary movements predominantly in the orofacial region and develops in approximately 20% of patients during long-term treatment with typical antipsychotics. The high prevalence of TD and its disabling and potentially irreversible clinical course is an important shortcoming for treatment with typical antipsychotics. The studies presented in this article evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP1A2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyskinesia, Drug-Induced

Share to Pharmacogenetics

Share to Receptors, Dopamine D2

Share to Receptors, Dopamine D3

Share to Risk Factors

Share to Schizophrenia

Source

Identifiers

PMID: 11179771
DOI: 10.1016/s0165-022x(00)00161-5

Genes

DRD3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.PMID 11179771Read ↗

Pharmacogenetics of antipsychotic-induced side effects.Semantic proximity Read ↗

Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics of tardive dyskinesia: an updated review of the literature.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced side effectsSemantic proximity Read ↗

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients.Semantic proximity Read ↗

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia.Semantic proximity Read ↗

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical StudiesSemantic proximity Read ↗

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.Semantic proximity Read ↗

Genetics of tardive dyskinesia.Semantic proximity Read ↗

Pharmacogenetics-Guided Advances in Antipsychotic Treatment.Semantic proximity Read ↗

Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia.Semantic proximity Read ↗

Pharmacogenetics of second-generation antipsychotics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.